Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy
US10611842B2 · kind B2 · utility
7Cited by
2References
15Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Jul 26, 2017 |
| Grant date | Apr 7, 2020 |
| Priority date | — |
| Expiry date | Jan 10, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Anti-SIRPα antibodies, including multi-specific anti-SIRPα antibodies, are provided, as are related compositions and methods. The antibodies of the disclosure bind to SIRPα and can block the interaction of CD47 on one cell with SIRPα on a phagocytic cell. The subject anti-SIRPα antibodies find use in various therapeutic methods. Embodiments of the disclosure include isolated antibodies and derivatives and fragments thereof, pharmaceutical formulations comprising one or more of the anti-SIRPα antibodies; and cell lines that produce the antibodies. Also provided are amino acid sequences of exemplary anti-SIRPα antibodies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.